# A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis

> **NCT01900574** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 35 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Golimumab

## Key facts

- **NCT ID:** NCT01900574
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-09
- **Primary completion:** 2015-02-18
- **Final completion:** 2022-09-01
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900574, "A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01900574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*